It has been recently described that disruption of the neural mechanisms of emotion-based decision making occurs in both chronic pain patients and in animal models of pain; moreover, it also has been shown that chronic pain causes morphological and functional changes in the prefrontal cortex that may be crucial for this decision-making dysfunction. However, it is not known whether pain alone is capable of altering the neuronal encoding of decision exhibited by prefrontal neurons. We have previously shown that naïve animals have risk-averse performance in the rodent gambling task, whereas chronic pain animals reverse their choice preference and become risk prone. Using this paradigm, we chronically implanted arrays of multielectrodes and recorded from neuronal ensembles in the orbitofrontal cortex of freely moving animals performing 4 sessions of the rodent gambling task: 2 in control conditions and 2 after the onset of inflammatory pain induced by complete Freund's adjuvant injection. Our results show that the instantaneous neuronal firing rate was correlated with the probability of choosing a specific lever in 62.5% of the neurons; however, although in the control sessions 61% of the neurons encoded the reward magnitude, after the pain onset only 16% of the neurons differentiated small from large rewards. Moreover, we found that the fraction of risk-sensitive neurons recorded in each session predicted the overall risk bias of the animal. Our data suggest that orbitofrontal cortex encoding of risk preference is compromised in chronic pain animals.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.pain.2012.04.011 | DOI Listing |
Scand J Gastroenterol
March 2025
Department of Abdominal surgery, Helsinki University Hospital, Helsinki, Finland.
Objectives: Extracorporeal shock wave lithotripsy (ESWL) with endotherapy (ET) is the first-line treatment in patients with chronic pancreatitis (CP) and main pancreatic duct stone (PDS). Our study aimed to evaluate factors that predict the outcome of ESWL in CP patients with PDS.
Methods: We retrospectively analyzed data of 166 patients with CP and radiopaque PDS.
J Pain Res
March 2025
Program of Physical Therapy, Department of Medical Rehabilitation Sciences, College of Applied Medical Sciences, King Khalid University, Abha, 61421, Saudi Arabia.
Background: Between half and three quarters of the working-age population in today's industrialized globe suffers from lower back pain. The presence of a myofascial trigger point-a hyperirritable painful area comprised of a small number of muscle fibers-identifies mechanical back pain sufferers as suffering from myofascial pain syndrome, a chronic pain disorder. This research objectives to determine whether mechanical back pain patients' pain severity and functional disabilities are influenced by electromagnetic field therapy.
View Article and Find Full Text PDFFront Neurosci
February 2025
Department of Urology, Huashan Hospital, Fudan University, Shanghai, China.
Background: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a prevalent condition in urology characterized by chronic pain. The pathogenesis of CP/CPPS remains unclear.
Methods: We enrolled 45 eligible CP/CPPS patients and 45 healthy volunteers.
Front Surg
February 2025
Department of Vascular Surgery, Tianjin First Central Hospital, Tianjin, China.
Persistent sciatic artery (PSA) is a rare anatomic variant disease with an incidence of approximately 0.025%-0.05% it is considered to be an axial congenital vascular malformation, which may be related to the failure of sciatic artery degeneration and iliofemoral artery dysplasia.
View Article and Find Full Text PDFTher Adv Musculoskelet Dis
March 2025
Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité-Universitätsmedizin Berlin, Berlin, Germany.
Background: Early treatment initiation is one of the strongest predictors of good treatment response in axial spondyloarthritis (axSpA). Recently, the Assessment in SpondyloArthritis International Society (ASAS) defined early axSpA as a diagnosis of axSpA with a duration of axial symptoms equal to or less than 2 years. Tofacitinib is a Janus kinase (JAK) inhibitor for the treatment of ankylosing spondylitis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!